Monsanto last week provided an update to its research and development pipeline, highlighting the advancement of four product candidates incorporating RNAi through the company's pipeline.
During a conference call held to discuss the pipeline, as well as Monsanto's fiscal first-quarter 2013 financial results, CTO Robert Fraley stressed the importance of having “more than one or two component technologies” to success in the ag-bio space.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
